Prospektive Phase-II-Studie zur neoadjuvanten Radiochemotherapie fortgeschrittener, operabler Mundhöhlenkarzinome
| Autor: | Dirk Rades, B. Dietl, Christof Hofele, Ingeborg Wildfang, R. Dammer, Johann H. Karstens, Rudat, André Eckardt |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry medicine.medical_treatment Standard treatment Head and neck cancer Phases of clinical research Cancer medicine.disease Carboplatin Radiation therapy chemistry.chemical_compound Otorhinolaryngology chemistry Internal medicine Carcinoma medicine Oral Surgery business Chemoradiotherapy |
| Zdroj: | Mund-, Kiefer- und Gesichtschirurgie. 6:117-121 |
| ISSN: | 1434-3940 1432-9417 |
| DOI: | 10.1007/s10006-002-0370-y |
| Popis: | PURPOSE The purpose of simultaneous chemoradiotherapy is to increase local-regional control and to decrease the incidence of distant metastases. Regimens containing cisplatin/5-FU chemotherapy are widely accepted as standard treatment in advanced head and neck cancer. Most studies reported promising response and survival data, but also severe mucosal toxicity. In recent years the newly developed drug Taxol demonstrated interesting activity in head and neck cancer as a single agent as well as in combination drug regimens. In the present outpatient phase II trial, we investigated the combination of Taxol/carboplatin with 40 Gy radiotherapy in a neoadjuvant setting of operable stage III/IV squamous cell carcinoma of the oral cavity and oropharynx. PATIENTS AND METHODS Fifty-three patients were enrolled in this trial during the period from May 1998 to October 2000 and received five cycles weekly of Taxol (40 mg/m2) and carboplatin (AUC 1.5) with conventional radiotherapy (40 Gy). Within 3-4 weeks after chemoradiotherapy resection of the primary tumor and the regional neck nodes was performed. RESULTS Fifty-two patients were evaluable for toxicity and response. Complete response was observed in 31 of 52 patients (CR 60%), and partial remission was seen in 21 of 52 patients (PR 40%). In 30 of 52 patients complete pathologic response (pCR 58%) was documented in the resection specimens. The 1-, 2-, and 3-year overall survival rate was calculated as 84%. CONCLUSION Our present results demonstrated impressive clinical and pathological response rates of concurrent Taxol/carboplatin and radiotherapy as a preoperative treatment modality in advanced oral and oropharyngeal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|